abrdn Life Sciences Investors (NYSE:HQL) Reaches New 12-Month High – Still a Buy?

Shares of abrdn Life Sciences Investors (NYSE:HQL) hit a new 52-week high on Monday . The stock traded as high as $20.20 and last traded at $20.2490, with a volume of 127466 shares. The stock had previously closed at $20.12.

abrdn Life Sciences Investors Stock Up 2.4%

The business has a fifty day simple moving average of $18.00 and a 200-day simple moving average of $17.27.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, May 21st were paid a $0.56 dividend. This represents a $2.24 annualized dividend and a dividend yield of 10.9%. The ex-dividend date was Thursday, May 21st.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several hedge funds have recently bought and sold shares of HQL. Geneos Wealth Management Inc. increased its stake in shares of abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after purchasing an additional 1,529 shares in the last quarter. Global Retirement Partners LLC boosted its position in shares of abrdn Life Sciences Investors by 187.8% in the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after purchasing an additional 4,593 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of abrdn Life Sciences Investors in the 4th quarter worth approximately $177,000. Evolve Private Wealth LLC purchased a new stake in shares of abrdn Life Sciences Investors in the 4th quarter worth approximately $199,000. Finally, Independent Financial Group LLC bought a new position in abrdn Life Sciences Investors during the 1st quarter valued at approximately $211,000. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.